radiotherapy

Led FAST-Forward, which cut breast radiotherapy from three weeks to one with no loss of effectiveness.

Radiation oncologist specialising in head and neck cancer who oversees clinical affairs at Poland's National Research Institute of Oncology.

Led the proton dose-escalation trial in prostate cancer and the comparative-effectiveness debate over proton therapy.

Created the low, intermediate and high-risk classification that every prostate cancer decision starts from.

Milan radiation oncologist leading ESTRO, Europe's radiotherapy and oncology society.

Physicist who invented the MR-linac, letting radiotherapy see and adapt to the tumour in real time.

Led the PORTEC trials that defined who needs radiotherapy for endometrial cancer and brought molecular classification into treatment decisions.

Led IMPORT LOW, which showed partial-breast radiotherapy is as effective as whole-breast treatment with fewer side effects.

London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.

Led CONVERT, which set the radiotherapy schedule for limited-stage small-cell lung cancer.

Radiation oncologist who built AI models from trial slides to decide which prostate cancer patients need hormone therapy.

Radiation oncologist who chairs the directorate of the University Cancer Center Inselspital in Bern.

Led SABR-COMET, the trial that showed treating a few metastases with high-dose radiation can prolong survival.

British radiation oncologist who led CHHiP, the trial that showed prostate cancer can be treated in 20 radiotherapy sessions rather than 37 with the same results, changing practice worldwide.

Adelaide radiation oncologist who chairs TROG's Scientific Committee and is its President Elect.

Radiation specialist who has directed QST Hospital in Chiba, Japan's pioneering carbon ion radiotherapy hospital, since April 2024.

Radiation oncologist behind the MACH-NC meta-analyses that proved chemoradiotherapy helps head and neck cancer, and the first FLASH-treated patient.

Led RTOG 0617, the trial that showed higher radiation doses do not help in stage III lung cancer and set today's 60 Gy standard.

Pioneering radiation oncologist at Aarhus who led the DAHANCA trials on hypoxia modification and radiotherapy for head and neck cancer.

Led the trials comparing stereotactic radiotherapy with surgery for operable early lung cancer.

Statistician who ran the START, FAST-Forward and POETIC trials that reshaped breast cancer radiotherapy and endocrine therapy.

Radiobiologist who discovered the FLASH effect: ultra-fast radiation spares healthy tissue while still killing tumours.

Zurich radiation oncologist and ESTRO Past-President, a leading voice on stereotactic radiotherapy for oligometastases.

Radiation oncologist who speaks for the Comprehensive Cancer Center Tübingen-Stuttgart and directs radiation oncology at Tübingen University Hospital.

Mayo Clinic radiation oncologist whose trials showed that focused radiosurgery preserves thinking and memory better than whole-brain radiotherapy for brain metastases, and that sparing the hippocampus reduces cognitive harm when whole-brain treatment is needed.

Sydney radiation oncologist who is President of TROG Cancer Research, Australasia's radiation oncology trials group.

Chairs NRG Oncology, the largest US radiotherapy cooperative group, and leads head and neck de-escalation trials.

Argentine diplomat leading the IAEA since 2019, whose Rays of Hope initiative expands radiotherapy and nuclear medicine access in low- and middle-income countries.

Radiation oncologist at the University of Chicago known for the oligometastasis concept and for research linking radiation with anti-tumour immunity.

Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects.

Pioneer of stereotactic body radiotherapy, whose RTOG 0236 trial made SBRT the standard for inoperable early lung cancer.

Weill Cornell pathologist-immunologist known for radiation-immunotherapy research; SITC Vice President.

Radiation oncologist who established stereotactic radiotherapy as a non-surgical option for primary kidney cancer.

Carbon-ion radiotherapy specialist who directs the Gunma University Heavy Ion Medical Center, Japan's first university-based carbon-ion cancer treatment facility.

Led the Canadian trials that established three-week breast radiotherapy and defined when nodal radiotherapy helps.

Radiation oncologist directing science and research at Masaryk Memorial Cancer Institute, with a research focus on brain tumours and brain metastases.